



## Preferred Drug List

### NEW DRUG REVIEW

**Proprietary Name:** Cimzia®

**Common Name:** Certolizumab pegol

**PDL Category:** GI- Inflammatory Bowel Agents

<u>Comparable Products</u>	<u>Preferred Drug List Status</u>
Enbrel®	Preferred
Humira®	Preferred
<b>Summary</b>	

**Indications and Usage:** Moderately to severely active Crohn's Disease in adults who have had an inadequate response to conventional therapy. Moderately to severely active Rheumatoid Arthritis (RA) in adults.<sup>1</sup>

**Mechanism of Action:** Binds to human TNF-alpha which inhibits inflammation to bones, cartilage, and tissue.<sup>1</sup>

**Dosage Forms:** Subcutaneous Injection: 200mg/ml single use prefilled syringe and 200mg lyophilized powder for reconstitution.

**Recommended Dosage:** Crohn's Disease: 400 mg initially and at Weeks 2 and 4. If response occurs, follow with 400 mg every four weeks. RA: 400 mg initially and at Weeks 2 and 4, followed by 200 mg every other week; for maintenance dosing, 400 mg every 4 weeks can be considered.<sup>1</sup>

**Common Adverse Drug Reactions:** Upper respiratory tract infection, rash, urinary tract infection.<sup>1</sup>

**Contraindications:** None<sup>1</sup>

**Manufacturer:** UCB, Inc.

**Analysis:** Cimzia® is a new TNF blocker indicated for the treatment of Crohn's Disease and RA. After initial dosing, every 4 week dosing may be considered for Cimzia®. It is the only PEGylated anti-TNF, offering selective affinity of TNF-alpha. In the trials used to gain FDA approval, Cimzia® was only compared to placebo. Response and remission rates appear to be comparable with currently available TNF blockers. Preferred alternatives appear on the Preferred Drug List, which have similar clinical efficacy and are more cost effective. Therefore, it is recommended that Cimzia® be added to the Preferred Drug List as a non-preferred drug with conditions.

**IME Recommendation:**

<input type="checkbox"/> Preferred Drug	<input type="checkbox"/> Recommended Drug
<input type="checkbox"/> Non-Preferred Drug	<input type="checkbox"/> Non-Recommended Drug
<input checked="" type="checkbox"/> Non-Preferred Drug with Conditions	

1. Cimzia® [package insert]. Smyrna, GA: UCB, Inc.; 2009.